|
|
|
| Effect of Roxastat Capsules in the treatment of renal anemia in chronic renal failure patients with maintenance hemodialysis |
| LIN Baoli JIN Lisi CHEN Zhi |
| Department of Pharmacy, Wenzhou Central Hospital, Zhejiang Province, Wenzhou 325000, China |
|
|
|
Abstract Objective To investigate the effect of Roxastat Capsules in the treatment of renal anemia in chronic renal failure patients with maintenance hemodialysis. Methods A total of 301 chronic renal failure patients with maintenance hemodialysis with renal anemia in Wenzhou Central Hospital, Zhejiang Province from October 2020 to June 2021 were selected, among which 235 patients were treated with subcutaneous injection of recombinant human erythropoietin injection as the conventional group and 66 patients were treated with Roxastat Capsules orally as the observation group. After matching by propensity score matching method, 66 patients were included in each group. The treatment time of the two groups was three months. The indexes of anemia, ferrum metabolism, and inflammation were compared between the two groups before and after treatment. The efficacy of the two groups was compared, and the occurrence of adverse reactions between the two groups during treatment was recorded. Results After treatment, hemoglobin (Hb), erythropoietin (EPO), ferrum (Fe), and transferrin (TRF) in two groups were higher than those before treatment, ferritin (FER) and C-reactive protein (CRP) were lower than those before treatment, and Hb, EPO, Fe, TRF, and FER of observation group were higher than those of conventional group, and CRP was lower than that of conventional group (P＜0.05). The clinical efficacy of observation group was better than that of conventional group, and the total incidence of adverse reactions was lower than that of conventional group (P＜0.05). Conclusion Roxastat Capsules in the treatment of renal anemia in chronic renal failure patients with maintenance hemodialysis, can improve anemia, promote ferrum metabolism, reduce inflammation and adverse reactions, the effect is significant.
|
|
|
|
|
|
[1] 苏超，卞显倩，王刚，等.生血宁与多糖铁治疗血液透析患者肾性贫血的疗效比较[J].临床肾脏病杂志，2020，20（4）：293-296，321.
[2] 吕晴，陈卫东，刘磊.维持性血液透析患者肾性贫血的多因素分析及相关性研究[J].中华全科医学，2021，19（5）：871-874.
[3] 蒲玲，丁国华.不同透析方式青中年透析患者的感染特征分析[J].医学研究杂志，2020，49（4）：157-162.
[4] 陈力平，冯明.NLR联合CRP与PCT对慢性肾衰竭维持性血液透析患者细菌感染的诊断价值[J].中华医院感染学杂志，2021，31（12）：14-16.
[5] 钱卫明.温肾活络补血方治疗维持性血液透析肾性贫血患者疗效观察[J].现代中西医结合杂志，2020，29（24）：2680-2683.
[6] 王金鑫，王杨威，张艺献，等.维持性血液透析患者血清低氧诱导通路相关指标水平与肾性贫血的相关性[J].中国实验诊断学，2020，24（11）：27-28.
[7] 付群英，梁颖.血液灌流联合维持性血液透析对肾衰患者肾性贫血和微炎症状态的影响[J].国际泌尿系统杂志，2020，40（5）：22-26.
[8] 黄碧红，贾守梅，钱璟，等.维持性血液透析患者血氨基末端脑钠肽前体水平与肾性贫血的相关性[J].中华肾脏病杂志，2020，36（5）：17-18.
[9] 李昌艳，刘娟，顾芳，等.静脉输注蔗糖铁联合重组人促红细胞生成素对维持血液透析肾性贫血患者的疗效与安全性分析[J].解放军医药杂志，2020，32（2）：51- 55.
[10] 杨洁，张利平，陈天怡，等.低氧诱导因子-脯氨酰羟化酶抑制剂治疗肾性贫血1例报告[J].中国实用内科杂志，2020，40（11）：13-15.
[11] 王培培，吴涛.口服罗沙司他对慢性肾脏病并肾性贫血的治疗效果观察[J].山东医药，2020，60（33）：73-75.
[12] 赖玮婧，刘芳，付平.慢性肾脏病评估及管理临床实践指南解读——从K/DOQI到KDIGO[J].中国实用内科杂志，2013，33（6）：448-453.
[13] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018修订版）[J].中华肾脏病杂志，2018，34（11）：17-18.
[14] 刘天成，王鹏飞.益肾补脾方对维持性血液透析肾性贫血患者生活质量及微炎症状态的影响[J].辽宁中医杂志，2021，36（5）：78-81.
[15] 何香芝.左卡尼汀联合促红细胞生成素治疗维持性血液透析肾性贫血临床效果研究[J].中国药物与临床，2020， 20（21）：3644-3646.
[16] 李琳，崔珺，崔艳，等.hs-CRP，NLR及FGF23对慢性肾衰竭维持性血液透析患者的预后评估价值[J].西部医学，2021，33（11）：24-26.
[17] 史亚男，胡志娟，赵鹏，等.低氧诱导因子-脯氨酰羟化酶抑制剂治疗血液透析患者肾性贫血的疗效和安全性分析[J].中国实用内科杂志，2020，40（11）：16-18.
[18] 王宁，刘亚，戴春.罗沙司他对透析合并肾性贫血患者的疗效[J].中国临床医生杂志，2022，50（5）：573- 576.
[19] 谷茜，景三辉，吴歌.罗沙司他口服治疗肾性贫血效果观察[J].山东医药，2022，62（12）：60-63.
[20] 陈中亚，田利霞，高雨亭.罗沙司他胶囊的制备及其初步质量评价[J].中国处方药，2022，20（4）：28-30.
[21] 沈雯雯，王伟，刘旻.罗沙司他治疗抗EPO抗体介导的纯红再障1例[J].安徽医学，2022，43（3）：365-366.
[22] 魏汪伶，涂芊茜，张文俊，等.罗沙司他治疗超高龄前列腺癌贫血1例[J].中国临床实用医学，2022，13（1）：65- 66.
[23] 王明光，张滨.罗沙司他新中间体的合成技术研究[J].化工设计通讯，2022，48（2）：202-204.
[24] 徐丹，冯霞，钟询龙.罗沙司他治疗肾性贫血效果的影响因素分析[J].中国医院药学杂志，2022，42（7）：732- 735.
[25] 张志杰，刘琳.维持性血液透析患者促红细胞生成素低反应性的相关影响因素分析[J].山西医药杂志，2020， 49（18）：10-14. |
|
|
|
